Free Trial
NASDAQ:ACHL

Achilles Therapeutics (ACHL) Stock Price, News & Analysis

Achilles Therapeutics logo
$1.48 0.00 (0.00%)
As of 03/26/2025

About Achilles Therapeutics Stock (NASDAQ:ACHL)

Key Stats

Today's Range
$1.48
$1.48
50-Day Range
$1.37
$1.49
52-Week Range
$0.63
$1.51
Volume
N/A
Average Volume
568,222 shs
Market Capitalization
$60.83 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Achilles Therapeutics plc, a biopharmaceutical company, develops precision T cell therapies to treat solid tumors. Its platform identifies mutations formed early in the development of cancer. The company offers PELEUS, a proprietary AI-powered bioinformatics platform, used to identify clonal neoantigens in a patient. It also develops CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. The company was formerly known as Achilles TX Limited and changed its name to Achilles Therapeutics Plc in February 2021. Achilles Therapeutics Plc was founded in 2016 and is headquartered in London, the United Kingdom.

Receive ACHL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Achilles Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ACHL Stock News Headlines

Crypto’s crashing…but we’re still profiting
Most traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess. The news is screaming fear. But while most traders watch their portfolios tank…
See More Headlines

ACHL Stock Analysis - Frequently Asked Questions

Achilles Therapeutics' stock was trading at $1.14 at the beginning of the year. Since then, ACHL stock has increased by 29.8% and is now trading at $1.48.
View the best growth stocks for 2025 here
.

Achilles Therapeutics plc (NASDAQ:ACHL) released its quarterly earnings results on Wednesday, August, 14th. The company reported ($0.41) earnings per share for the quarter, hitting the consensus estimate of ($0.41).

Achilles Therapeutics (ACHL) raised $176 million in an IPO on Wednesday, March 31st 2021. The company issued 9,800,000 shares at a price of $17.00-$19.00 per share. JPMorgan, BofA Securities, Piper Sandler, Chardan, Oppenheimer & Co. and Kempen & Co. acted as the underwriters for the IPO.

Shares of ACHL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Achilles Therapeutics investors own include Digital Turbine (APPS), Aquestive Therapeutics (AQST), CRISPR Therapeutics (CRSP), ChargePoint (CHPT) and NVIDIA (NVDA).

Company Calendar

Last Earnings
8/14/2024
Today
4/25/2025
Next Earnings (Estimated)
5/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ACHL
Fax
N/A
Employees
250
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-69,670,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$3.49 per share
Price / Book
0.42

Miscellaneous

Free Float
38,889,000
Market Cap
$60.83 million
Optionable
Not Optionable
Beta
1.25
The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

This page (NASDAQ:ACHL) was last updated on 4/25/2025 by MarketBeat.com Staff
From Our Partners